Apathy in Dementia Methylphenidate Trial (ADMET)

Phase 2 Completed 60 enrolled Johns Hopkins Bloomberg School of Public Health Johns Hopkins University · collab Medical University of South Carolina · collab National Institute on Aging (NIA) · collab University of Toronto · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial that will examine the efficacy and safety of methylphenidate for the treatment of clinically significant apathy in patients with Alzheimer's dementia.

Timeline

Start: 2010-06
Primary completion: 2012-08
Completion: 2012-08

Publications

Rosenberg PB, Lanctot KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer JE, ADMET Investigators. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013 Aug;74(8):810-6. doi: 10.4088/JCP.12m08099.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylphenidate	Small molecule	20 mg	Oral

Apathy in Dementia Methylphenidate Trial (ADMET)

Summary

Timeline

Publications

Drugs

Indications